Current Appointments & Affiliations
Assistant Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).
Journal Article Clin Cancer Res · October 15, 2019 PURPOSE: Bendamustine and rituximab (BR) has been established as a superior frontline therapy over R-CHOP in the treatment of follicular lymphoma (FL). Yttrium-90 Ibritumomab tiuxetan (90YIT) is an effective consolidation strategy after chemotherapy induct ... Full text Link to item Cite–positive relapsed and refractory, diffuse large ‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy
Journal Article Cancer · November 15, 2017 BACKGROUNDThe impact of MYC proto‐oncogene, basic helix‐loop‐helix (MYC) translocations (with or without additional rearrangements involving the B‐cell lymphoma 2 [BCL2 Full text CiteOutcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Journal Article Journal of Clinical Oncology · July 10, 2017 Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce th ... Full text CiteRecent Grants
A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2025 - 2030A single-arm, open-label, Phase 2 study evaluating subcutaneous administration of isatuximab, administered by an On Body Delivery System, in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and/or refractory
Clinical TrialPrincipal Investigator · Awarded by Sanofi US Services, Inc. · 2025 - 2030Phase 1b Dose Expansion Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis
Clinical TrialPrincipal Investigator · Awarded by Nexcella, Inc. · 2025 - 2030View All Grants
Education, Training & Certifications
Philadelphia College of Osteopathic Medicine ·
2011
D.O.